• Arch Med Sci · Jan 2020

    The incidence of recurrent cardiovascular events among acute coronary syndrome patients treated with generic or original clopidogrel in relation to their sociodemographic and clinical characteristics. The Aegean study.

    • Nikolaos G Patsourakos, Matina Kouvari, Apostolos Kotidis, Kallirroi I Kalantzi, Maria E Tsoumani, Filippos Anastasiadis, Panagiotis Andronikos, Theano Aslanidou, Petros Efraimidis, Anastasios Georgiopoulos, Kalliopi Gerakiou, Eleni Grigoriadou-Skouta, Panagiotis Grigoropoulos, Dionysios Hatzopoulos, Athanasios Kartalis, Anastasios Lyras, Gerasimos Markatos, Aristeidis Mikrogeorgiou, Ioannis Myroforou, Anestis Orkopoulos, Pavlos Pavlidis, Charalampos Petras, Maria Riga, Marina Skouloudi, Nikolaos Smyrnioudis, Konstantinos Thomaidis, Grammatiki E Tsikouri, Emmanuel I Tsikouris, Konstantinos Zisimos, Panagiotis Vavoulis, Maria-Gabriella Vitali, George Vitsas, Constantinos Vogiatzidis, Stylianos Chantanis, Stefanos Fousas, Demosthenes B Panagiotakos, and Alexandros D Tselepis.
    • Cardiology Department, Tzaneio Hospital of Piraeus, Piraeus, Greece.
    • Arch Med Sci. 2020 Jan 1; 16 (5): 1013-1021.

    IntroductionThe use of generic drugs is continuously growing; however, there are limited epidemiological data regarding the therapeutic equivalence of each original drug formulation with its generic counterparts. We evaluated the 12-month composite endpoint of recurrent acute myocardial infarction, ischaemic stroke, cardiac deaths, or hospitalisation due to a major bleeding in acute coronary syndrome (ACS) patients treated with original clopidogrel or a generic clopidogrel formulation, in relation to sociodemographic and clinical characteristics.Material And MethodsConsecutive Greek ACS patients (n = 1194) hospitalised in the Aegean islands and the Attica region were enrolled. Clopidogrel treatment was recorded either as original clopidogrel hydrogen sulphate (Plavix®/Iscover®) or as a generic clopidogrel besylate formulation (Clovelen®). The composite endpoint was recorded at 12-month follow-up.ResultsThe 12-month composite endpoint was 3.9% (4.6% in the Aegean islands and 3.5% in the Attica area, p > 0.05). The respective incidence in men was 4.0% and in women 3.8% (p > 0.05). Overall, generic and original clopidogrel use was 87% and 13% of patients, respectively. No significant differences were observed between original and generic clopidogrel use and 12-month composite endpoint incidence. Subgroup analysis with gender, region of residence, and clinical and lifestyle factors as strata did not reveal any significant outcomes. Haemorrhage incidence did not exceed 1% in the total sample.ConclusionsThe use of a generic clopidogrel besylate formulation was quite high in both urban and insular areas of Greece and had similar efficacy and safety profile with the original clopidogrel salt, supporting the routine use of this low-cost generic clopidogrel in the management of cardiovascular disease patients.Copyright: © 2020 Termedia & Banach.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…